Healthcare Industry News: thrombin
News Release - March 20, 2007
Seattle Genetics Appoints Dr. Tom Reynolds Chief Medical OfficerBOTHELL, Wash.--(HSMN NewsFeed)--Seattle Genetics, Inc. (Nasdaq:SGEN ) today announced that Thomas C. Reynolds, M.D., Ph.D., has joined the company as Chief Medical Officer. In this role, Dr. Reynolds will oversee clinical and regulatory activities across the company's product portfolio focused on cancer and autoimmune disease.
"Tom has more than 15 years of drug development expertise and a proven track record of building and leading clinical teams and programs," said Clay B. Siegall, Ph.D., President and Chief Executive Officer of Seattle Genetics. "His experience in clinical and regulatory affairs, from preclinical development through the FDA approval process, will enhance our efforts to bring our multiple product candidates to patients."
"Seattle Genetics' diverse product pipeline has significant potential to address many unmet medical needs in cancer," said Dr. Reynolds. "The company's experienced management team, industry-leading antibody-drug conjugate technology and strategic collaborations such as the recent SGN-40 agreement with Genentech, combine to make this an exciting opportunity for me. I look forward to contributing to the company's future progress."
Dr. Reynolds was at Zymogenetics from 2002 to 2007, most recently as Vice President, Medical Affairs, where he oversaw the clinical development and recent BLA filing of rhthrombin and led the Medical Affairs department. Previously, he held various positions at Targeted Genetics, including Vice President, Clinical Affairs, and before that was at Somatix Therapy (acquired by Cell Genesys in 1997). Dr. Reynolds holds a B.A. in Chemistry from Dartmouth College and both a Ph.D. in Biophysics and M.D. from Stanford University.
About Seattle Genetics
Seattle Genetics is a biotechnology company developing monoclonal antibody-based therapies for the treatment of multiple types of cancer, including lymphoma, multiple myeloma, leukemia and solid tumors. The company has an exclusive worldwide license agreement with Genentech to develop and commercialize SGN-40. In addition, Seattle Genetics has developed proprietary antibody-drug conjugate (ADC) technology comprised of highly potent synthetic drugs and stable linkers for attaching the drugs to monoclonal antibodies. The company has collaborations for its ADC technology with a number of leading biotechnology and pharmaceutical companies, including Genentech, Bayer, CuraGen, Progenics and MedImmune, as well as an ADC co-development agreement with Agensys. More information can be found at www.seattlegenetics.com.
Certain of the statements made in this press release are forward-looking, such as those, among others, relating to advancement of the company's product pipeline. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include risks related to adverse clinical results as our product candidates move into and advance in clinical trials, risks inherent in early-stage development and failure by Seattle Genetics to secure or maintain relationships with collaborators. More information about the risks and uncertainties faced by Seattle Genetics is contained in the company's filings with the Securities and Exchange Commission. Seattle Genetics disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Source: Seattle Genetics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.